• Oxford Nanopore and Lonza Team Up, Medidata and Sanofi Vaccines Collaborate, More

    Feb 29 | Bio-IT World | Oxford Nanopore and Lonza have teamed up to cGMP validate and commercialize a first-of-its-kind novel test to accurately determine multiple critical quality attributes of mRNA products by directly sequencing both the DNA template and the messenger RNA; Parse updates whole transcriptome kit; and more. More
  • Ginkgo Bioworks Announces Three Acquisitions

    Feb 28 | Bio-IT World | Ginkgo Bioworks announced three acquisitions today: Reverie Labs, Proof Diagnostics, and Patch Biosciences. The acquisitions will expand Ginkgo’s capabilities for large-scale AI foundation models, its library of RNA programmable, non-Cas enzymes, and its machine learning models and downstream assays. More
  • Follow the Money: Cancer Early Detection Tests, Self-Sampling Solutions Expansion, Multiple Product Advancement

    Feb 28 | Bio-IT World | Freenome will advance the pipeline of single-cancer and tailored multi-cancer early detection tests built on its multiomics platform; Capitainer plans to advance its journey toward becoming the foremost provider of self-sampling solutions with new funding, including scaling up production capacity, enhancing sales and marketing strategies, and launching new products; COUR will advance multiple, wholly owned product candidates that leverage the company’s immune tolerance platform, including Phase 2a proof-of-concept clinical studies in Myasthenia Gravis and Type 1 Diabetes, and other pipeline opportunities; and more. More
  • Ultima’s Silicon Wafer Sequencing Launches on $100 Genome, Part Per Million Accuracy

    Feb 27 | Bio-IT World | Among the sequencing news at AGBT earlier this month, Ultima Genomics announced the commercial launch of its UG 100 ultra-high throughput sequencing platform. More
  • Why It Is Vital to Help IT and Scientists Collaborate

    Feb 23 | Bio-IT World | In the race to unlock the power of artificial intelligence (AI) for business, it is tempting to focus on the need to strategically leverage data—indeed, this is a message that I reinforce constantly when onboarding new clients. But there’s a step that must happen first. More
  • Proteomics Approach Working Its Way To The Clinic For Stubborn Cancers

    Feb 22 | Bio-IT World | For roughly half of patients with recurrence of often-deadly glioblastoma multiforme (GBM), their tumors are characterized by cells that look a lot like healthy neurons. The mimicry trick was discovered by proteomics, which has opened a view to tumor alterations unavailable through genetics alone. More
  • Latest Oral Insulin Drug Making Its Way To Clinical Trials

    Feb 20 | Bio-IT World | More than a century has passed since the discovery of insulin, the world's first life-saving treatment for diabetes, and it is still being delivered via injection despite several brushes with success in developing an oral version of the drug. Hope is again on the horizon with the emergence of an oral nanotherapeutic formulation of insulin that comes with the possibility of reducing if not eliminating hypoglycemic events. More
  • New Vaccinology Rulebook Needed To Outsmart ‘Part-Time Pathogens’

    Feb 15 | Bio-IT World | Researchers at University of California San Diego School of Medicine have found that the rules of vaccinology need to be reversed for Staphylococcus aureus (SA), the common and sometimes dangerous bacteria that humans encounter shortly after birth and are continuously exposed to for the remainder of their life. More
  • Study Establishes ENPP1 As A Biomarker For Immunotherapy Benefit

    Feb 14 | Bio-IT World | Researchers in California have shown that breast cancer patients with RNA expression levels of ENPP1 (ectonucleotide pyrophosphatase/phosphodiesterase 1) in the bottom 50th percentile can confidently be treated with Keytruda (pembrolizumab) as well as surgery. Their cancer would have a zero percent chance of metastasizing in seven years. More
  • Novel NGS-Based Assay Has Seemingly Limitless Virus Detection Potential

    Feb 13 | Bio-IT World | Scientists at the Center for Infection and Immunity (CII) at Columbia University Mailman School of Public Health have created a next-generation sequencing (NGS) technology that employs oligonucleotides (oligos)—short single strands of synthetic DNA—as bait for relevant targets of detection. More
View more articles
Bio IT World Lead Gen


Riffyn’s pioneering cloud system, Riffyn Nexus, delivers 2X faster development cycles and 4X productivity gains to the world’s most advanced scientific R&D organizations. Its process-centric experiment design, data capture, and data analytics overcome the limitations of ELN and LIMS systems. Its adaptive data integration engine delivers results that are always ready for machine learning.
Read more here!

Trends from the Trenches

Bio-IT World’s Trends from the Trenches podcast delivers your insider’s look at the science, technology, and executive trends driving the life sciences through conversations with industry leaders. BioTeam co-founder Stan Gloss brings years of industry experience in science, data, and technology to conversations exploring what is driving data and discovery, and what’s coming next.
Listen today!